JP2013523821A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013523821A5 JP2013523821A5 JP2013503845A JP2013503845A JP2013523821A5 JP 2013523821 A5 JP2013523821 A5 JP 2013523821A5 JP 2013503845 A JP2013503845 A JP 2013503845A JP 2013503845 A JP2013503845 A JP 2013503845A JP 2013523821 A5 JP2013523821 A5 JP 2013523821A5
- Authority
- JP
- Japan
- Prior art keywords
- antihypertensive agent
- implant
- timolol
- antihypertensive
- intraocular
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229940030600 antihypertensive agent Drugs 0.000 claims 12
- 239000002220 antihypertensive agent Substances 0.000 claims 12
- 239000007943 implant Substances 0.000 claims 9
- 230000004410 intraocular pressure Effects 0.000 claims 6
- 229920000642 polymer Polymers 0.000 claims 4
- 238000013268 sustained release Methods 0.000 claims 3
- 239000012730 sustained-release form Substances 0.000 claims 3
- TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 claims 2
- -1 levobonolol Chemical compound 0.000 claims 2
- 229920001610 polycaprolactone Polymers 0.000 claims 2
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 claims 2
- 229960004605 timolol Drugs 0.000 claims 2
- 229960002368 travoprost Drugs 0.000 claims 2
- MKPLKVHSHYCHOC-AHTXBMBWSA-N travoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)COC1=CC=CC(C(F)(F)F)=C1 MKPLKVHSHYCHOC-AHTXBMBWSA-N 0.000 claims 2
- QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 claims 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 claims 1
- 229930182837 (R)-adrenaline Natural products 0.000 claims 1
- NWIUTZDMDHAVTP-KRWDZBQOSA-N (S)-betaxolol Chemical compound C1=CC(OC[C@@H](O)CNC(C)C)=CC=C1CCOCC1CC1 NWIUTZDMDHAVTP-KRWDZBQOSA-N 0.000 claims 1
- ZUIFJYRNWWNOPB-PPHPATTJSA-N 5-bromo-n-(4,5-dihydro-1h-imidazol-2-yl)quinoxalin-6-amine;(2s)-1-(tert-butylamino)-3-[(4-morpholin-4-yl-1,2,5-thiadiazol-3-yl)oxy]propan-2-ol Chemical compound C1=CC2=NC=CN=C2C(Br)=C1NC1=NCCN1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 ZUIFJYRNWWNOPB-PPHPATTJSA-N 0.000 claims 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 1
- XYLJNLCSTIOKRM-UHFFFAOYSA-N Alphagan Chemical compound C1=CC2=NC=CN=C2C(Br)=C1NC1=NCCN1 XYLJNLCSTIOKRM-UHFFFAOYSA-N 0.000 claims 1
- ISZJXIYRLAGBMH-IQMDKZJJSA-N CC(C)(C)NC[C@H](O)COc1nsnc1N1CCOCC1.CCNC(=O)CCC\C=C/CC1C(O)CC(O)[C@@H]1\C=C\C(O)CCc1ccccc1 Chemical compound CC(C)(C)NC[C@H](O)COc1nsnc1N1CCOCC1.CCNC(=O)CCC\C=C/CC1C(O)CC(O)[C@@H]1\C=C\C(O)CCc1ccccc1 ISZJXIYRLAGBMH-IQMDKZJJSA-N 0.000 claims 1
- 101150109738 Ptger4 gene Proteins 0.000 claims 1
- QCHFTSOMWOSFHM-UHFFFAOYSA-N SJ000285536 Natural products C1OC(=O)C(CC)C1CC1=CN=CN1C QCHFTSOMWOSFHM-UHFFFAOYSA-N 0.000 claims 1
- 229940022663 acetate Drugs 0.000 claims 1
- 239000008186 active pharmaceutical agent Substances 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 230000003276 anti-hypertensive effect Effects 0.000 claims 1
- 229960002610 apraclonidine Drugs 0.000 claims 1
- IEJXVRYNEISIKR-UHFFFAOYSA-N apraclonidine Chemical compound ClC1=CC(N)=CC(Cl)=C1NC1=NCCN1 IEJXVRYNEISIKR-UHFFFAOYSA-N 0.000 claims 1
- NWIUTZDMDHAVTP-UHFFFAOYSA-N betaxolol Chemical compound C1=CC(OCC(O)CNC(C)C)=CC=C1CCOCC1CC1 NWIUTZDMDHAVTP-UHFFFAOYSA-N 0.000 claims 1
- 229960004324 betaxolol Drugs 0.000 claims 1
- 229960002470 bimatoprost Drugs 0.000 claims 1
- AQOKCDNYWBIDND-FTOWTWDKSA-N bimatoprost Chemical group CCNC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)CCC1=CC=CC=C1 AQOKCDNYWBIDND-FTOWTWDKSA-N 0.000 claims 1
- 229960003679 brimonidine Drugs 0.000 claims 1
- 229940046336 brimonidine / timolol Drugs 0.000 claims 1
- 229930003827 cannabinoid Natural products 0.000 claims 1
- 239000003557 cannabinoid Substances 0.000 claims 1
- 229940065144 cannabinoids Drugs 0.000 claims 1
- LWAFSWPYPHEXKX-UHFFFAOYSA-N carteolol Chemical compound N1C(=O)CCC2=C1C=CC=C2OCC(O)CNC(C)(C)C LWAFSWPYPHEXKX-UHFFFAOYSA-N 0.000 claims 1
- 229960001222 carteolol Drugs 0.000 claims 1
- 229920002301 cellulose acetate Polymers 0.000 claims 1
- OCUJLLGVOUDECM-UHFFFAOYSA-N dipivefrin Chemical compound CNCC(O)C1=CC=C(OC(=O)C(C)(C)C)C(OC(=O)C(C)(C)C)=C1 OCUJLLGVOUDECM-UHFFFAOYSA-N 0.000 claims 1
- 229960000966 dipivefrine Drugs 0.000 claims 1
- 229960005139 epinephrine Drugs 0.000 claims 1
- AVOLMBLBETYQHX-UHFFFAOYSA-N etacrynic acid Chemical compound CCC(=C)C(=O)C1=CC=C(OCC(O)=O)C(Cl)=C1Cl AVOLMBLBETYQHX-UHFFFAOYSA-N 0.000 claims 1
- 229960003199 etacrynic acid Drugs 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 229960001160 latanoprost Drugs 0.000 claims 1
- GGXICVAJURFBLW-CEYXHVGTSA-N latanoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1 GGXICVAJURFBLW-CEYXHVGTSA-N 0.000 claims 1
- 229940065183 latanoprost / timolol Drugs 0.000 claims 1
- NSHPHXHGRHSMIK-IWQSFCKSSA-N latrunculin B Natural products C[C@H]1CC[C@@H]2C[C@@H](C[C@@](O)(O2)[C@@H]3CSC(=O)N3)OC(=O)C=C(C)/CCC=C/1 NSHPHXHGRHSMIK-IWQSFCKSSA-N 0.000 claims 1
- 229960004771 levobetaxolol Drugs 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 229960001416 pilocarpine Drugs 0.000 claims 1
- 229920001983 poloxamer Polymers 0.000 claims 1
- 229960003712 propranolol Drugs 0.000 claims 1
- 229940044601 receptor agonist Drugs 0.000 claims 1
- 239000000018 receptor agonist Substances 0.000 claims 1
- 229960004317 unoprostone Drugs 0.000 claims 1
- TVHAZVBUYQMHBC-SNHXEXRGSA-N unoprostone Chemical compound CCCCCCCC(=O)CC[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O TVHAZVBUYQMHBC-SNHXEXRGSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32142210P | 2010-04-06 | 2010-04-06 | |
| US61/321,422 | 2010-04-06 | ||
| PCT/US2011/031265 WO2011127064A2 (en) | 2010-04-06 | 2011-04-05 | Sustained-release reservoir implants for intracameral drug delivery |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015090706A Division JP2015166361A (ja) | 2010-04-06 | 2015-04-27 | 前房内薬剤送達のための徐放性リザーバーインプラント |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013523821A JP2013523821A (ja) | 2013-06-17 |
| JP2013523821A5 true JP2013523821A5 (enExample) | 2014-05-08 |
Family
ID=44065364
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013503845A Pending JP2013523821A (ja) | 2010-04-06 | 2011-04-05 | 前房内薬剤送達のための徐放性リザーバーインプラント |
| JP2015090706A Pending JP2015166361A (ja) | 2010-04-06 | 2015-04-27 | 前房内薬剤送達のための徐放性リザーバーインプラント |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015090706A Pending JP2015166361A (ja) | 2010-04-06 | 2015-04-27 | 前房内薬剤送達のための徐放性リザーバーインプラント |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US20130017243A1 (enExample) |
| EP (1) | EP2555749B1 (enExample) |
| JP (2) | JP2013523821A (enExample) |
| KR (1) | KR20130086131A (enExample) |
| CN (1) | CN102905688B (enExample) |
| AU (1) | AU2011237788A1 (enExample) |
| BR (1) | BR112012025581A2 (enExample) |
| CA (1) | CA2795706A1 (enExample) |
| RU (1) | RU2012146630A (enExample) |
| WO (1) | WO2011127064A2 (enExample) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7431710B2 (en) | 2002-04-08 | 2008-10-07 | Glaukos Corporation | Ocular implants with anchors and methods thereof |
| US20050244458A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Sustained release intraocular implants and methods for treating ocular neuropathies |
| US8778398B2 (en) | 2008-11-04 | 2014-07-15 | Jazz Pharmaceuticals, Inc. | Immediate release formulations and dosage forms of gamma-hydroxybutyrate |
| WO2010093945A2 (en) | 2009-02-13 | 2010-08-19 | Glaukos Corporation | Uveoscleral drug delivery implant and methods for implanting the same |
| US12478503B2 (en) | 2009-05-18 | 2025-11-25 | Glaukos Corporation | Implants with controlled drug delivery features and methods of using same |
| CA2762536C (en) | 2009-05-18 | 2019-05-21 | Dose Medical Corporation | Drug eluting ocular implant |
| US10206813B2 (en) | 2009-05-18 | 2019-02-19 | Dose Medical Corporation | Implants with controlled drug delivery features and methods of using same |
| AU2010256558B2 (en) | 2009-06-03 | 2013-10-03 | Forsight Labs, Llc | Anterior segment drug delivery |
| AU2011232408B2 (en) | 2010-03-24 | 2015-07-30 | Jazz Pharmaceuticals, Inc. | Controlled release dosage forms for high dose, water soluble and hygroscopic drug substances |
| EP2571526B1 (en) | 2010-05-17 | 2019-03-13 | Novaer Holdings, Inc. | Drug delivery devices for delivery of ocular therapeutic agents |
| EP2654715B1 (en) | 2010-11-24 | 2017-01-25 | Dose Medical Corporation | Drug eluting ocular implant |
| US8715713B2 (en) | 2011-04-29 | 2014-05-06 | Allergan, Inc. | Solvent cast film sustained release latanoprost implant |
| US10245178B1 (en) | 2011-06-07 | 2019-04-02 | Glaukos Corporation | Anterior chamber drug-eluting ocular implant |
| WO2014120866A1 (en) | 2013-01-31 | 2014-08-07 | Icon Bioscience, Inc. | Sustained release formulations for the treatment of intraocular pressure or glaucoma |
| AU2014216112B2 (en) * | 2013-02-15 | 2019-02-21 | Allergan, Inc. | Sustained drug delivery implant |
| BR112015022161B1 (pt) * | 2013-03-15 | 2020-11-24 | Allergan, Inc | Implante intraocular biodegradavel, uso do mesmo e metodo para fazer o mesmo |
| US10517759B2 (en) | 2013-03-15 | 2019-12-31 | Glaukos Corporation | Glaucoma stent and methods thereof for glaucoma treatment |
| ES2740352T3 (es) * | 2013-11-14 | 2020-02-05 | Eyed Pharma | Dispositivo ocular |
| US20150342875A1 (en) | 2014-05-29 | 2015-12-03 | Dose Medical Corporation | Implants with controlled drug delivery features and methods of using same |
| US10507101B2 (en) | 2014-10-13 | 2019-12-17 | W. L. Gore & Associates, Inc. | Valved conduit |
| US9669012B2 (en) | 2014-10-30 | 2017-06-06 | Textile-Based Delivery, Inc. | Delivery systems |
| CN104587850A (zh) * | 2015-01-11 | 2015-05-06 | 王丽莉 | 一种聚偏氟乙烯中空纤维膜的制备方法 |
| US10398662B1 (en) | 2015-02-18 | 2019-09-03 | Jazz Pharma Ireland Limited | GHB formulation and method for its manufacture |
| US20160296532A1 (en) | 2015-04-13 | 2016-10-13 | Forsight Vision5, Inc. | Ocular Insert Composition of a Semi-Crystalline or Crystalline Pharmaceutically Active Agent |
| WO2017040853A1 (en) | 2015-09-02 | 2017-03-09 | Glaukos Corporation | Drug delivery implants with bi-directional delivery capacity |
| WO2017053885A1 (en) | 2015-09-25 | 2017-03-30 | Glaukos Corporation | Punctal implants with controlled drug delivery features and methods of using same |
| RU2620249C1 (ru) * | 2015-12-17 | 2017-05-23 | Федеральное государственное автономное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации | Многослойный биодеградируемый глазной имплантат с дозированным высвобождением лекарственного вещества и способ его изготовления |
| JP7003110B2 (ja) | 2016-04-20 | 2022-01-20 | ドーズ メディカル コーポレーション | 生体吸収性眼球薬物送達デバイス |
| US11504347B1 (en) | 2016-07-22 | 2022-11-22 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11602512B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11986451B1 (en) | 2016-07-22 | 2024-05-21 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| UY37341A (es) | 2016-07-22 | 2017-11-30 | Flamel Ireland Ltd | Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada |
| US12186296B1 (en) | 2016-07-22 | 2025-01-07 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11602513B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12478604B1 (en) | 2016-07-22 | 2025-11-25 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12171869B2 (en) | 2016-09-23 | 2024-12-24 | Incept, Llc | Intracameral drug delivery depots |
| JP2019530556A (ja) * | 2016-09-30 | 2019-10-24 | リンセラ コーポレイション | 二重領域眼球用デバイスによる高精度薬物送達 |
| US11406533B2 (en) | 2017-03-17 | 2022-08-09 | W. L. Gore & Associates, Inc. | Integrated aqueous shunt for glaucoma treatment |
| US20180263936A1 (en) | 2017-03-17 | 2018-09-20 | Jazz Pharmaceuticals Ireland Limited | Gamma-hydroxybutyrate compositions and their use for the treatment of disorders |
| JP7770768B6 (ja) * | 2017-10-13 | 2025-12-05 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 繊毛病に関連する疾患の治療方法 |
| RU185437U1 (ru) * | 2018-04-12 | 2018-12-05 | федеральное государственное бюджетное образовательное учреждение высшего образования "Ульяновский государственный университет" | Устройство для герметизации капсул алюминиевых |
| WO2019222482A1 (en) * | 2018-05-16 | 2019-11-21 | Spirox, Inc. | Allergic rhinitis drug delivery implant |
| CA3110653A1 (en) | 2018-08-29 | 2020-03-05 | W. L. Gore & Associates, Inc. | Drug therapy delivery systems and methods |
| BR112021006027A2 (pt) | 2018-11-19 | 2021-06-29 | Jazz Pharmaceuticals Ireland Limited | formulações de fármaco resistente a álcool |
| US11678983B2 (en) | 2018-12-12 | 2023-06-20 | W. L. Gore & Associates, Inc. | Implantable component with socket |
| WO2020178695A1 (en) | 2019-03-01 | 2020-09-10 | Flamel Ireland Limited | Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state |
| TW202139986A (zh) | 2020-02-21 | 2021-11-01 | 愛爾蘭商爵士製藥愛爾蘭有限責任公司 | 治療原發性嗜睡症之方法 |
| US11975087B2 (en) * | 2020-03-30 | 2024-05-07 | Colgate-Palmolive Company | Sulfate-free personal care compositions and methods for preventing and treating pollution damage to skin |
| WO2021247690A1 (en) * | 2020-06-03 | 2021-12-09 | Glaukos Corporation | Rho kinase inhibitor releasing implants and related methods of use |
| US12527691B2 (en) | 2021-11-05 | 2026-01-20 | W. L. Gore & Associates, Inc. | Fluid drainage devices, systems, and methods |
| US11583510B1 (en) | 2022-02-07 | 2023-02-21 | Flamel Ireland Limited | Methods of administering gamma hydroxybutyrate formulations after a high-fat meal |
| US11779557B1 (en) | 2022-02-07 | 2023-10-10 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| EP4658242A1 (en) | 2023-02-03 | 2025-12-10 | Tris Pharma, Inc. | Low sodium oxybate once nightly composition |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5352708A (en) | 1992-09-21 | 1994-10-04 | Allergan, Inc. | Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents |
| US5516522A (en) * | 1994-03-14 | 1996-05-14 | Board Of Supervisors Of Louisiana State University | Biodegradable porous device for long-term drug delivery with constant rate release and method of making the same |
| DE60040876D1 (de) * | 1999-10-21 | 2009-01-02 | Alcon Inc | Medikamentenzuführeinrichtung |
| US6375972B1 (en) * | 2000-04-26 | 2002-04-23 | Control Delivery Systems, Inc. | Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof |
| US20040175410A1 (en) * | 2000-04-26 | 2004-09-09 | Control Delivery Systems, Inc. | Sustained release device and method for ocular delivery of carbonic anhydrase inhibitors |
| MXPA04011004A (es) * | 2002-05-07 | 2005-01-25 | Control Delivery Sys Inc | Procesos para formar un dispositivo de administracion de farmaco. |
| AR042917A1 (es) * | 2003-01-24 | 2005-07-06 | Control Delivery Sys Inc | Dispositivo de liberacion sostenida para la administracion ocular de agentes adrenergicos y uso de agentes adrenergicos para su preparacion |
| CN100594899C (zh) * | 2003-01-24 | 2010-03-24 | 控制递送系统有限公司 | 经眼部递送碳酸酐酶抑制剂的持续释放系统和方法 |
| AU2004292957C1 (en) * | 2003-11-13 | 2011-04-28 | Eyepoint Pharmaceuticals Us, Inc. | Injectable sustained release implant having a bioerodible matrix core and a bioerodible skin |
| CA2553381C (en) * | 2004-01-20 | 2011-03-22 | Allergan, Inc. | Compositions for localized therapy of the eye, comprising preferably triamcinolone acetonide and hyaluronic acid |
| US8722097B2 (en) * | 2004-04-30 | 2014-05-13 | Allergan, Inc. | Oil-in-water method for making polymeric implants containing a hypotensive lipid |
| US7799336B2 (en) * | 2004-04-30 | 2010-09-21 | Allergan, Inc. | Hypotensive lipid-containing biodegradable intraocular implants and related methods |
| CA2601864A1 (en) * | 2005-04-08 | 2006-10-19 | Surmodics, Inc. | Sustained release implants and methods for subretinal delivery of bioactive agents to treat or prevent retinal disease |
| CA2624174A1 (en) * | 2005-09-28 | 2007-04-05 | The Trustees Of The University Of Pennsylvania | Self-assembled biodegradable polymersomes |
| UY30883A1 (es) * | 2007-01-31 | 2008-05-31 | Alcon Res | Tapones punctales y metodos de liberacion de agentes terapeuticos |
| US8231892B2 (en) * | 2007-05-24 | 2012-07-31 | Allergan, Inc. | Biodegradable drug delivery system |
| US20080299176A1 (en) * | 2007-05-30 | 2008-12-04 | Yu-Chin Lai | Drug delivery device comprising crosslinked polyurethane-siloxane-containing copolymers |
| ES2538838T3 (es) * | 2007-09-07 | 2015-06-24 | Mati Therapeutics Inc. | Método para preparar insertos de fármacos para liberación sostenida de agentes terapéuticos |
| EP2512389B1 (en) * | 2009-12-16 | 2015-09-02 | Allergan, Inc. | Intracameral devices for sustained delivery |
-
2011
- 2011-04-05 EP EP11714895.7A patent/EP2555749B1/en not_active Not-in-force
- 2011-04-05 BR BR112012025581A patent/BR112012025581A2/pt not_active IP Right Cessation
- 2011-04-05 JP JP2013503845A patent/JP2013523821A/ja active Pending
- 2011-04-05 WO PCT/US2011/031265 patent/WO2011127064A2/en not_active Ceased
- 2011-04-05 RU RU2012146630/15A patent/RU2012146630A/ru not_active Application Discontinuation
- 2011-04-05 KR KR1020127029009A patent/KR20130086131A/ko not_active Withdrawn
- 2011-04-05 CN CN201180023027.7A patent/CN102905688B/zh not_active Expired - Fee Related
- 2011-04-05 US US13/583,183 patent/US20130017243A1/en not_active Abandoned
- 2011-04-05 AU AU2011237788A patent/AU2011237788A1/en not_active Abandoned
- 2011-04-05 CA CA2795706A patent/CA2795706A1/en not_active Abandoned
-
2014
- 2014-09-10 US US14/482,039 patent/US20150104491A1/en not_active Abandoned
-
2015
- 2015-04-27 JP JP2015090706A patent/JP2015166361A/ja active Pending
-
2016
- 2016-05-19 US US15/159,418 patent/US20160256382A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013523821A5 (enExample) | ||
| JP5696121B2 (ja) | α−２アドレナリン受容体アゴニスト含有生分解性眼内インプラント | |
| EP2555749B1 (en) | Sustained-release reservoir implants for intracameral drug delivery | |
| JP6100782B2 (ja) | 緑内障および高眼圧症を治療するための活性剤の徐放送達 | |
| JP5484911B2 (ja) | 眼内使用のための環状脂質インプラントの製造法 | |
| ES2624448T3 (es) | Implantes poliméricos de agonistas alfa-2 adrenérgicos biodegradables | |
| JP2012521997A5 (enExample) | ||
| CN106604695B (zh) | 用于在眼中实现持续药物释放的方法和生物相容性组合物 | |
| RU2013102030A (ru) | Композиции наноструктурированного апрепитанта, способ их получения и содержащие их фармацевтические композиции | |
| JP2013526572A5 (enExample) | ||
| JP2017526655A5 (enExample) | ||
| JP7636334B2 (ja) | 治療物質の眼投与のための薬物送達組成物及びその使用法 | |
| TW200400055A (en) | Ophthalmic formulation with novel gum composition | |
| JP2004528267A (ja) | 選択的シクロオキシゲナーゼ−２阻害性薬物の眼処方 | |
| NZ595294A (en) | Intraocular sustained release drug delivery systems and methods for treating ocular conditions | |
| JP2007535539A5 (enExample) | ||
| JP2016513109A (ja) | 持続型薬物送達インプラント | |
| EP1765284A1 (en) | Retinoid-containing sustained release intraocular drug delivery systems and related methods of manufacturing | |
| CN103561769A (zh) | 医药制剂 | |
| TW201043211A (en) | Punctal plugs | |
| WO2019200181A1 (en) | Methods and compositions for sustained release microparticles for ocular drug delivery | |
| CN103550223A (zh) | 红细胞膜包裹的眼用药物的新用途 | |
| JP2014515383A5 (enExample) | ||
| JP6213560B2 (ja) | 薬剤送達システムならびに開放隅角緑内障および高眼圧症を治療する方法 | |
| JP2013510845A5 (enExample) |